Dihydroartemisinin inhibits Epstein-Barr virus reactivation and replication targeting lytic proteins: insights for drug repurposing
This study identifies dihydroartemisinin as a repurposed drug that inhibits EBV reactivation and replication by targeting the lytic protein BZLF1.
Antiviral Research · Aug 28, 2026Peer-reviewedMicrobiology